HealthCo Healthcare and Wellness REIT (ASX: HCW) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

HealthCo Healthcare and Wellness REIT Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $418.13 million
P/E Ratio 67.62
Dividend Yield 2.71%
Shares Outstanding 550.18 million
Earnings per share -0.160
Dividend per share 0.08
Year To Date Return 6.90%
Earnings Yield 1.48%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • HealthCo Healthcare and Wellness REIT (ASX: HCW)
    Latest News

    Person handing out $50 notes, symbolising ex-dividend date.
    Dividend Investing

    Buy these ASX dividend shares for 6%+ yields

    Analysts expect these stocks to provide income investors with big yields in the coming years.

    Read more »

    Different Australian dollar notes in the palm of two hands, symbolising dividends.
    Dividend Investing

    3 high-yield ASX dividend stocks named as buys

    Analysts think big returns could be on offer with these buy-rated stocks.

    Read more »

    Hand of a woman carrying a bag of money, representing the concept of saving money or earning dividends.
    Dividend Investing

    These ASX dividend shares could be top buys in November

    Analysts think these shares could be great options for income investors.

    Read more »

    Woman holding $50 notes and smiling.
    Dividend Investing

    3 ASX dividend shares to supercharge your passive income

    Looking for an income boost? Analysts say these shares are buys.

    Read more »

    Senior woman with caregiver in the garden
    Healthcare Shares

    A 'golden era' is coming for these ASX healthcare shares

    Here's why Blackwattle Partners sees tailwinds ahead for one particular category of healthcare shares.

    Read more »

    Happy young couple saving money in piggy bank.
    Dividend Investing

    Want a 6%+ yield? 3 ASX dividend shares to buy this week

    Analysts expect these buy-rated stocks to provide investors with big yields.

    Read more »

    Middle age caucasian man smiling confident drinking coffee at home.
    Dividend Investing

    These buy-rated ASX dividend shares offer 6% yields

    Analysts are bullish on these income options. Here's what they are forecasting.

    Read more »

    A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
    Dividend Investing

    Analysts name 4 ASX dividend shares to buy for passive income

    Let's see what sort of income these shares could provide investors.

    Read more »

    Person holding Australian dollar notes, symbolising dividends.
    Dividend Investing

    3 high-yield ASX dividend shares that are great buys right now

    Analysts have put buy ratings on these stocks. Let's see what they offer income investors.

    Read more »

    Person handing out $50 notes, symbolising ex-dividend date.
    Dividend Investing

    Buy these ASX dividend stocks with 7%+ yields

    Analysts expect these stocks to make it rain dividends for their shareholders.

    Read more »

    Middle age caucasian man smiling confident drinking coffee at home.
    Dividend Investing

    Should you buy BHP and these ASX dividend shares?

    What are analysts saying about these income stocks?

    Read more »

    Happy man holding Australian dollar notes, representing dividends.
    Dividend Investing

    3 ASX dividend stocks with 7%+ yields to buy now

    Analysts say these buy-rated shares will provide big dividend yields.

    Read more »

    Frequently Asked Questions

    Yes, HealthCo Healthcare and Wellness REIT has historically paid four unfranked unitholder distributions a year.

    HealthCo Healthcare and Wellness REIT generally pays its unitholder distributions in February, May, August, and November.

    HealthCo Healthcare and Wellness REIT listed on the ASX on 6 September 2021.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    30 Dec 2024 $0.0210 0.00% Final 26 Feb 2025
    27 Sep 2024 $0.0210 0.00% Interim 22 Nov 2024
    27 Jun 2024 $0.0200 0.00% Final 22 Aug 2024
    27 Mar 2024 $0.0200 0.00% Interim 22 May 2024
    28 Dec 2023 $0.0200 0.00% Interim 21 Feb 2024
    28 Sep 2023 $0.0200 0.00% Interim 29 Nov 2023
    29 Jun 2023 $0.0200 0.00% Final 30 Aug 2023
    01 May 2023 $0.0188 0.00% Interim 23 Jun 2023
    29 Dec 2022 $0.0188 0.00% Interim 24 Feb 2023
    29 Sep 2022 $0.0188 0.00% Interim 25 Nov 2022
    29 Jun 2022 $0.0225 0.00% Final 22 Aug 2022
    30 Mar 2022 $0.0225 0.00% Interim 20 May 2022
    30 Dec 2021 $0.0300 0.00% Interim 25 Feb 2022

    HCW ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About HealthCo Healthcare and Wellness REIT

    HealthCo Healthcare and Wellness REIT (ASX: HCW) owns and manages a portfolio of commercial health and wellness real estate assets. The REIT is under the umbrella of HMC Capital (ASX: HMC), a listed asset manager that invests on behalf of individuals, large institutions, and super funds.

    HealthCo Healthcare and Wellness REIT holds a $1.6 billion portfolio of 36 properties including hospitals, aged care, childcare, life sciences and research facilities as well as primary care and wellness assets. The portfolio covers Queensland, New South Wales, Victoria, and Western Australia with a weighted average lease expiry (WALE) of 12 years. 

    HCW Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    16 Jan 2026 $0.76 $-0.01 -1.30% 356,175 $0.76 $0.77 $0.76
    15 Jan 2026 $0.77 $-0.01 -1.29% 573,547 $0.77 $0.79 $0.76
    14 Jan 2026 $0.78 $0.01 1.31% 525,292 $0.76 $0.78 $0.76
    13 Jan 2026 $0.77 $0.02 2.67% 363,257 $0.75 $0.77 $0.75
    12 Jan 2026 $0.75 $0.02 2.74% 377,945 $0.73 $0.75 $0.73
    09 Jan 2026 $0.73 $-0.01 -1.36% 172,155 $0.75 $0.75 $0.73
    08 Jan 2026 $0.74 $0.01 1.37% 324,125 $0.73 $0.75 $0.73
    07 Jan 2026 $0.73 $0.01 1.38% 970,145 $0.73 $0.74 $0.73
    06 Jan 2026 $0.73 $0.01 1.39% 276,505 $0.72 $0.73 $0.72
    05 Jan 2026 $0.72 $0.00 0.00% 1,017,171 $0.73 $0.74 $0.72
    02 Jan 2026 $0.72 $-0.01 -1.38% 422,709 $0.73 $0.74 $0.72
    31 Dec 2025 $0.73 $0.01 1.39% 331,733 $0.72 $0.73 $0.72
    30 Dec 2025 $0.72 $0.00 0.00% 534,683 $0.72 $0.73 $0.72
    29 Dec 2025 $0.72 $-0.01 -1.37% 804,313 $0.74 $0.74 $0.72
    24 Dec 2025 $0.73 $-0.01 -1.36% 449,292 $0.74 $0.75 $0.73
    23 Dec 2025 $0.74 $-0.01 -1.35% 690,109 $0.74 $0.76 $0.74
    22 Dec 2025 $0.74 $-0.01 -1.33% 1,657,333 $0.76 $0.76 $0.74
    19 Dec 2025 $0.75 $-0.01 -1.32% 1,606,226 $0.76 $0.76 $0.75
    18 Dec 2025 $0.76 $0.01 1.32% 2,676,474 $0.77 $0.77 $0.76
    17 Dec 2025 $0.76 $-0.01 -1.31% 630,161 $0.77 $0.78 $0.76

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    27 Aug 2025 Kelly O'Dwyer Buy 21,658 $16,893
    As advised by the company. Tranche 2 of 2 of the acquisition of units pursuant to participation in the FY25 voluntary non-executive director unit acquisition arrangement as summarised in HCW's Product Disclosure Statement dated 2 August 2021.
    27 Aug 2025 Joseph Carrozzi Buy 21,047 $16,416
    As advised by the company. Tranche 2 of 2 of the acquisition of units pursuant to participation in the FY25 voluntary non-executive director unit acquisition arrangement as summarised in HCW's Product Disclosure Statement dated 2 August 2021.
    27 Aug 2025 Natalie Meyenn Buy 25,565 $19,940
    As advised by the company. Tranche 2 of 2 of the acquisition of units pursuant to participation in the FY25 voluntary non-executive director unit acquisition arrangement as summarised in HCW's Product Disclosure Statement dated 2 August 2021.
    27 Feb 2025 Kelly O'Dwyer Buy 16,377 $16,049
    As advised by the company. Tranche 1 of 2 of the acquisition of units
    pursuant to participation in the FY25
    voluntary non-executive director unit
    acquisition arrangement as summarised in
    HCW's Product Disclosure Statement dated 2
    August 2021.
    27 Feb 2025 Natalie Meyenn Buy 19,361 $18,973
    As advised by the company. Tranche 1 of 2 of the acquisition of units
    pursuant to participation in the FY25
    voluntary non-executive director unit
    acquisition arrangement as summarised in
    HCW's Product Disclosure Statement dated 2
    August 2021.
    27 Feb 2025 Joseph Carrozzi Buy 16,079 $15,757
    As advised by the company. Tranche 1 of 2 of the acquisition of units
    pursuant to participation in the FY25
    voluntary non-executive director unit
    acquisition arrangement as summarised in
    HCW's Product Disclosure Statement dated 2
    August 2021.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Christopher Graham Roberts Non-Executive Director Aug 2021
    Dr Roberts has over 40 years of experience in the medical device industry serving a number of senior management positions. He was the former CEO of Cochlear from 2004 to 2015 and is presently a member of the Cochlear Foundation Board and a Non-Executive Director of HMC Capital Partners Fund 1, Atmo Biosciences Ltd, Centenary Institute of Medical Research and Nutromics Pty Ltd. He was also the Executive Vice President of ResMed from 1992 to 2003, and a director until 2017. Chris was a former Chair of Research Australia from 2004 to 2010. He was Chair of The Engineering and Design Institute London (TEDI London) (resigned on 19 May 2023).
    Ms Stephanie Mei-Nga Lai Non-Executive Director Aug 2021
    Ms Lai has over 25 years of experience and is a former Transaction Services partner of Deloitte and KPMG. She has experience providing due diligence and advisory services, including forecast reviews to listed entities, sovereign wealth funds, wealth managers and private equity. She is Chair of the Risk Committee.
    Mr David Anthony Di Pilla Non-Executive Director Jul 2021
    Mr Pilla led the team that founded the consortium which led to the ultimate establishment of HMC Capital Limited in 2016. Since this time, the HMC Group has grown from its initial Masters portfolio to today being an alternative asset manager with assets under management of approximately $18.5 billion. David has over 30 years of experience in investment banking, strategic advisory and consulting, and corporate leadership as a Director and CEO. During his 20-year investment banking career, David was Managing Director of UBS Investment Bank for over 15 years and during this time led some of Australia's transactions across corporate mergers and acquisitions, and equity and debt capital markets. Prior to his time at UBS, David reached the position of Vice President, Investment Banking at JP Morgan.
    Hon Kelly Megan O'Dwyer Non-Executive Director Aug 2021
    Hon O'Dwyer previously served in the Australian Parliament as a Senior Cabinet Minister holding a number of key economic portfolios including Minister for Jobs and Industrial Relations, Minister for Revenue and Financial Services, Minister for Small Business, and Assistant Treasurer. She also served on the Cabinet's Budget Committee (the Expenditure Review Committee) and held the portfolios of Minister for Women, as well as Minister Assisting the Prime Minister with the Public Service. Prior to entering Parliament, Kelly worked in law, government and finance and brings insights across a range of sectors including funds management, superannuation, workplace relations, foreign investment, law and banking. Kelly is also a Non-Executive Director of Barrenjoey Capital Partners Group Holdings Pty Ltd and the National Reconstruction Fund Corporation.
    Mr Joseph Carrozzi Non-Executive ChairmanNon-Executive Director Aug 2021
    Mr Carrozzi has over 30 years of experience as a managing partner in the Big 4 professional services firms. He has experience in infrastructure, health and medical research as well as sectors which are highly regulated. He is currently the President of Business NSW, the Chair of the Centenary Institute for Medical Research and AKG Group (a private employment services business), as well as a board member of Football Australia. Joseph was formerly Chair of the Sydney Harbour Federation Trust and Deputy Chair of the NSW Institute of Sport and a former board member of Western Sydney University and the National Intermodal Corporation. He is on the UNSW Dean's Advisory Council for the Faculty of Medicine. He is member of the Risk Committee.
    Ms Natalie Jane Meyenn Non-Executive Director Aug 2021
    Ms Meyenn has over 25 years of experience in financial services and investing globally. She was Head and Chair of the Investment Committee for MLC Private Equity, and is currently co-founder of an agriculture investment firm and adviser and/or investment committee member to a small number of asset management, private equity and non profits including New Energy Nexus and Yielco Investments. She worked in investment banking (mergers and acquisitions, capital markets and public finance) for Goldman Sachs and Bear Stearns in New York and Sydney and for the World Bank on micro-credit, project finance and climate impact mitigation in Asia, Africa and the Pacific Islands. She is member of the Risk Committee.
    Mr Andrew Selim Company SecretaryGeneral Counsel
    -
    Andrew Selim Company SecretaryGeneral Counsel
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Home Consortium Developments Limited 89,871,409 16.34%
    J P Morgan Nominees Australia Pty Limited 86,335,952 15.69%
    HSBC Custody Nominees (Australia) Limited 62,321,284 11.33%
    Home Consortium Limited 35,034,393 6.37%
    Citicorp Nominees Pty Limited 34,995,999 6.36%
    BNP Paribas Noms Pty Ltd 22,633,093 4.11%
    BNP Paribas Nominees Pty Ltd (HUB24 Custodial Serv Ltd) 7,369,385 1.34%
    Netwealth Investments Limited (Wrap Services A/C) 6,901,705 1.25%
    National Nominees Limited 5,866,514 1.07%
    Buttonwood Nominees Pty Ltd 5,734,186 1.04%
    BNP Paribas Nominees Pty Ltd (Agency Lending A/C) 4,547,184 0.83%
    Netwealth Investments Limited (Super Services a/c) 2,527,985 0.46%
    Mr David Edward Ogden and Mrs Amanday Jay Ogden (D & A Ogden Family A/C) 2,403,833 0.44%
    Ubs Nominees Pty Ltd 2,290,401 0.42%
    HSBC Custody Nominees (Australia) Limited A/C 2 2,111,567 0.38%
    BNP Paribas Nominees Pty Ltd (IB AU Noms Retailclient) 1,806,826 0.33%
    Aldaoud Pty Ltd (Aldaoud Family A/C) 1,500,000 0.27%
    Neweconomy Com AU Nominees Pty Limited (900 Account) 1,497,949 0.27%
    Glengallan Investments Pty Ltd 1,188,249 0.22%
    Premium Capital (Aust) Pty Ltd 1,040,020 0.19%

    Profile

    since

    Note